

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ATROPINE safely and effectively. See full prescribing information for ATROPINE.

ATROPINE injection, for intramuscular use

Initial U.S. Approval: 1973

INDICATIONS AND USAGE

Atropine, a cholinergic muscarinic antagonist, is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity as well as organophosphorus or carbamate insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds) (1).

DOSAGE AND ADMINISTRATION

- Atropine is intended as an initial treatment as soon as symptoms appear; definitive medical care should be sought immediately. (2.1)
- Administer each dose of the 2 mg Atropine autoinjector into the patient's mid-lateral outer thigh (2.1).
- Dosage for Mild Symptoms** If the patient experiences two or more mild symptoms, administer one injection intramuscularly into the mid-lateral thigh. If, at any time after the first dose, the patient develops any of the severe symptoms, administer two additional injections intramuscularly in rapid succession (2.2).
- Dosage for Severe Symptoms** If a patient has any of the severe symptoms, immediately administer three injections intramuscularly into the patient's mid-lateral thigh in rapid succession (2.2).

DOSAGE FORMS AND STRENGTHS

Injection: 1.67 mg/0.7 mL atropine base (equivalent to **2 mg** atropine sulfate) in a single-dose prefilled autoinjector (3)

CONTRAINDICATIONS

None (4)

WARNINGS AND PRECAUTIONS

- Cardiovascular (CV) Risks** Tachycardia, palpitations, premature ventricular contractions, flutter, fibrillation, etc. Use caution in patients with known CV disease or conduction problems. (5.1)
- Heat Injury** May inhibit sweating and lead to hyperthermia; avoid excessive exercising and heat exposure. (5.2)
- Acute Glaucoma** May precipitate in susceptible individuals. (5.3)
- Urinary Retention:** Administer with caution in patient with bladder outflow obstruction. (5.4)
- Pyloric Stenosis** May convert into complete obstruction. (5.5)
- Exacerbation of Chronic Lung Disease** Atropine may cause inspiration of bronchial secretions and formation of dangerous viscid plugs in individuals with chronic lung disease; monitor respiratory status. (5.6)
- Hypersensitivity** Atropine may cause hypersensitivity reactions, including anaphylaxis (5.7)

ADVERSE REACTIONS

Mild to moderate pain may be experienced at the site of injection. Common adverse reactions of atropine include dryness of the mouth, blurred vision, dry eyes, photophobia, confusion, headache, dizziness, tachycardia, palpitations, flushing, urinary hesitance or retention, constipation, abdominal pain, abdominal distention, nausea, vomiting, loss of libido, and impotency (6.1, 6.2).

To report SUSPECTED ADVERSE REACTIONS, contact **Rafa Laboratories at 1-386-418-7911** or **FDA at 1-800-FDA-1088** or www.fda.gov/medwatch

DRUG INTERACTIONS

Pralidoxime may potentiate the effect of atropine (7.1).

Barbiturates atropine may potentiate the effect of barbiturates (7.2)

See **17** for **PATIENT COUNSELING INFORMATION** and FDA-approved patient labeling.

Revised: 2/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Administration Information
- 2.2 Dosage Information
- 2.3 Additional Care Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Cardiovascular Risks
- 5.2 Heat Injury
- 5.3 Acute Glaucoma
- 5.4 Urinary Retention
- 5.5 Pyloric Stenosis
- 5.6 Exacerbation of Chronic Lung Disease
- 5.7 Hypersensitivity

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

- 7.1 Pralidoxime
- 7.2 Barbiturates

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

10 OVERDOSAGE

- 10.1 Symptoms
- 10.2 Treatment

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

- 16.1 How Supplied
- 16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Atropine is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity as well as organophosphorus or carbamate insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds).

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Information

- Three (3) Atropine autoinjectors should be available for use in each patient at risk for nerve agent or organophosphate insecticide poisoning; one (1) for mild symptoms plus two (2) more for severe symptoms [*see Dosage and Administration (2.2)*].
- Only administer Atropine to patients experiencing symptoms of organophosphorus poisoning in a situation where exposure is known or suspected. The Atropine autoinjector is intended as an initial treatment of the muscarinic symptoms of insecticide or nerve agent poisonings as soon as symptoms appear; definitive medical care should be sought immediately.
- In general, atropine should not be used until cyanosis has been overcome since atropine may produce ventricular fibrillation and possible seizures in the presence of hypoxia.
- The Atropine autoinjector should be used by persons who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication, but may be administered by a caregiver or by self-administration if a trained provider is not available.
- Close supervision of all treated patients is indicated for at least 48 to 72 hours.
- In severe poisonings, concurrent administration of an anticonvulsant (preferably a benzodiazepine) may be warranted if seizure is suspected in the unconscious individual because overt jerking may not be apparent because of the effects of the poison [*see Drug Interactions (7.2)*].
- In poisonings caused by organophosphorous nerve agents and insecticides it may also be helpful to concurrently administer a cholinesterase reactivator such as pralidoxime chloride [*see Drug Interactions (7.1)*].
- The injection site is the mid-lateral thigh area. The Atropine autoinjector can inject through clothing. However, make sure pockets at the injection site are empty. People who may not have a lot of fat at the injection site should also be injected in the mid-lateral thigh, but before giving the injection, bunch up the thigh to provide a thicker area for injection.

2.2 Dosage Information

Dosage for Mild Symptoms in Adults and Pediatric Patients Weighing More Than 41 kg (90 Pounds)

First Dose: If the patient experiences two or more mild symptoms of nerve agent (nerve gas) or insecticide exposure listed in Table 1, administer **one** (1) Atropine injection intramuscularly into the mid-lateral outer thigh.

Additional Doses: If, at any time after the first dose, the patient develops any of the severe symptoms listed in Table 1, administer two (2) additional Atropine injections intramuscularly in rapid succession.

Wait 10 to 15 minutes for Atropine to take effect. If, after 10 to 15 minutes, the patient does not develop any of the severe symptoms listed in Table 1, no additional Atropine injections are recommended.

If possible, a person other than the patient should administer the second and third 2 mg Atropine autoinjectors.

Dosage for Severe Symptoms in Adults and Pediatric Patients Weighing More Than 41 kg (90 Pounds)

If a patient is either unconscious or has any of the severe symptoms listed in Table 1, immediately administer three (3) Atropine injections intramuscularly into the patient's mid-lateral outer thigh in rapid succession.

Table 1: Common Signs/Symptoms of Organophosphorus and/or Carbamate Poisoning

<u>MILD symptoms include:</u>	<u>SEVERE symptoms include:</u>
<ul style="list-style-type: none">• Blurred vision or miosis• Unexplained excessive lacrimation• Unexplained excessive nasopharyngeal secretions• Increased salivation• Chest tightness, difficulty breathing, wheezing, or coughing• Tremors throughout the body or muscular twitching• Nausea, vomiting, abdominal cramping, or diarrhea• Tachycardia or bradycardia	<ul style="list-style-type: none">• Altered mental status• Loss of consciousness• Respiratory distress• Excessive secretions from the lungs/airway• Severe muscular twitching, generalized weakness or paralysis• Involuntary urination and/or defecation• Convulsions or seizures

2.3 Additional Care Instructions

Environmental

- All patients should be evacuated immediately from the contaminated environment.
- Protective masks and clothing should be used when available.
- Aggressive and safe decontamination procedures should be undertaken as soon as possible.
- If dermal exposure has occurred, clothing should be removed and the hair and skin washed thoroughly with sodium bicarbonate or alcohol as soon as possible.
- Physicians and/or other medical personnel assisting evacuated patients of nerve and insecticide poisoning should avoid exposing themselves to contamination by the patient's clothing.

Medical

- Medical help should be sought immediately.
- Emergency care of the severely poisoned individual should include removal of oral and bronchial secretions, maintenance of a patent airway, supplemental oxygen and, if necessary, artificial ventilation.
- Severe difficulty in breathing requires artificial respiration in addition to the use of Atropine since Atropine is not dependable in reversing the weakness or paralysis of the respiratory muscles.
- Refer to the illustrated dose-specific Instructions for Use for autoinjector administration instructions.
- Antidotes, such as Atropine, should not be relied upon solely to provide complete protection from chemical nerve agents and insecticide poisoning.

3 DOSAGE FORMS AND STRENGTHS

Each single-dose Atropine autoinjector contains atropine base 1.67 mg/0.7 mL (equivalent to atropine sulfate 2 mg/0.7 mL) in a sterile solution for intramuscular injection.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Cardiovascular Risks

Cardiovascular adverse reactions reported in the literature for atropine include, but are not limited to, sinus tachycardia, palpitations, premature ventricular contractions, atrial flutter, atrial fibrillation, ventricular flutter, ventricular fibrillation, cardiac syncope, asystole, and myocardial infarction [see *Adverse Reactions* (6)]. In patients with a recent myocardial infarction and/or severe coronary artery disease, there is a possibility that atropine-induced tachycardia may cause ischemia, extend or initiate myocardial infarcts, and stimulate ventricular ectopy and fibrillation. Atropine should be used with caution in patients with known cardiovascular disease or cardiac conduction problems.

5.2 Heat Injury

Atropine may inhibit sweating which, in a warm environment or with excessive exercise, can lead to hyperthermia and heat injury. To the extent feasible, avoid excessive exercise and heat exposure [see *Adverse Reactions* (6)].

5.3 Acute Glaucoma

Atropine may cause acute glaucoma and should be administered with caution in patients at risk for acute glaucoma or who have severe narrow angle glaucoma. Monitor for signs and symptoms of intraocular pressure, as appropriate.

5.4 Urinary Retention

Atropine may cause urinary retention and should be administered with caution to patients with clinically significant bladder outflow obstruction.

5.5 Pyloric Stenosis

Atropine may cause complete pyloric obstruction in patients with partial pyloric stenosis. These patients should be monitored for gastrointestinal symptoms following administration of Atropine.

5.6 Exacerbation of Chronic Lung Disease

Atropine may cause thickening of bronchial secretions and formation of dangerous viscid plugs in individuals with chronic lung disease. Respiratory status should be monitored in individuals with chronic lung disease following administration of Atropine.

5.7 Hypersensitivity

Atropine can cause hypersensitivity reactions, including anaphylactic reactions [see *Adverse Reactions (6)*]. Medical supervision is necessary in patients who have had previous anaphylactic reactions to atropine and require treatment for organophosphorus or nerve agent poisoning.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Cardiovascular Risks [see *Warnings and Precautions (5.1)*]
- Heat Injury [see *Warnings and Precautions (5.2)*]
- Acute Glaucoma [see *Warnings and Precautions (5.3)*]
- Urinary Retention [see *Warnings and Precautions (5.4)*]
- Pyloric Stenosis [see *Warnings and Precautions (5.5)*]
- Exacerbation of Chronic Lung Disease [see *Warnings and Precautions (5.6)*]
- Hypersensitivity [see *Warnings and Precautions (5.7)*]

The following adverse reactions associated with the use of atropine were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Injection Site Reactions

Mild to moderate pain may be experienced at the site of injection.

Adverse Reactions at Recommended Dosages

The major and most common side effects of atropine can be attributed to its antimuscarinic action. These include dryness of the mouth, blurred vision, dry eyes, photophobia, confusion, headache, dizziness, fatigue, tachycardia, palpitations, flushing, urinary hesitance or retention, constipation, abdominal pain, abdominal distention, nausea, vomiting, loss of libido, and impotency. Anhidrosis may produce heat intolerance and impairment of temperature regulation especially in a hot environment.

Hypersensitivity

Hypersensitivity reactions will occasionally occur with atropine; these are usually seen as skin rashes, on occasion progressing to exfoliation. Anaphylactic reactions have occurred.

Additional Adverse Reactions to Atropine by Organ System

The following adverse reactions were reported in published literature for atropine in both adults and pediatric patients:

Cardiovascular: Sinus tachycardia, supraventricular tachycardia, junctional tachycardia, ventricular tachycardia, bradycardia, palpitations, ventricular arrhythmia, ventricular flutter, ventricular fibrillation, atrial arrhythmia, atrial fibrillation, atrial ectopic beats, ventricular premature contractions, bigeminal beats, trigeminal beats, nodal extrasystole, ventricular extrasystole, supraventricular extrasystole, asystole, cardiac syncope, prolongation of sinus node recovery time, cardiac dilation, left ventricular failure, myocardial infarction, intermittent nodal rhythm (no P wave), prolonged P wave, shortened PR segment, R on T phenomenon, shortened RT duration, widening and flattening of QRS complex, prolonged QT interval, flattening of T wave, repolarization abnormalities, altered ST-T waves, retrograde conduction, transient AV dissociation, increased blood pressure, decreased blood pressure, labile blood pressure, weak or impalpable peripheral pulses.

Eye: Mydriasis, pupils poorly reactive to light, decreased contrast sensitivity, decreased visual acuity, decreased accommodation, cycloplegia, strabismus, heterophoria, cyclophoria, acute angle closure glaucoma, conjunctivitis, keratoconjunctivitis sicca, blindness, tearing, dry conjunctiva, irritated eyes, crusting of eyelid, blepharitis.

Gastrointestinal: Paralytic ileus, decreased bowel sounds, delayed gastric emptying, decreased food absorption, dysphagia.

General: Hyperpyrexia, lethargy, somnolence, chest pain, excessive thirst, weakness, syncope, insomnia, tongue chewing, dehydration, feeling hot.

Special Investigations: Leukocytosis, hyponatremia, elevated BUN, elevated hemoglobin, elevated erythrocytes, low hemoglobin, hypoglycemia, hyperglycemia, hypokalemia, increase in photic stimulation on EEG, signs of drowsiness on EEG, runs of alpha waves on EEG, alpha waves (EEG) blocked upon opening eyes.

Metabolic: Failure to feed.

Central Nervous System: Ataxia, hallucinations (visual or aural), seizures (generally tonic-clonic), abnormal movements, coma, stupor, amnesia, diminished tendon reflexes, hyperreflexia, muscle twitching, opisthotonos, Babinski's reflex/Chaddock's reflex, hypertonia, dysmetria, muscle clonus, sensation of intoxication, difficulty concentrating, vertigo, dysarthria.

Psychiatric: Agitation, restlessness, delirium, paranoia, anxiety, mental disorders, mania, withdrawn behavior, behavior changes.

Genitourinary: Difficulty in micturation, urine urgency, distended urinary bladder, bed-wetting.

Pulmonary: Tachypnea, slow respirations, shallow respirations, breathing difficulty, labored respirations, inspiratory stridor, laryngitis, laryngospasm, pulmonary edema, respiratory failure, subcostal recession.

Dermatologic: Dry mucous membranes, dry warm skin, oral lesions, dermatitis, petechiae, rash, macular rash, papular rash, maculopapular rash, scarlatiniform rash, erythematous rash, sweating/moist skin, cold skin, cyanosed skin, salivation.

Adverse Reactions Caused by Inadvertent Injection

Administering additional 2 mg Atropine autoinjectors by mistake in the absence of actual nerve agent or insecticide poisoning may cause an overdose of atropine which could result in temporary incapacitation (inability to walk properly, see clearly or think clearly for several or more hours). Patients with cardiac disease may be at risk for serious adverse events, including death.

Adverse Reactions Observed in Pediatric Patients after Inappropriate Administration of Atropine

Amitai et al. (JAMA 1990) evaluated the safety of an atropine autoinjector in a case series of 240 children who received the atropine inappropriately (i.e., no nerve agent exposure) during the 1990 Gulf War Period. Overall, severity of atropinization followed a nonlinear correlation with dose. Estimated doses up to 0.045 mg/kg produced no signs of atropinization. Estimated doses between 0.045 mg/kg to 0.175 mg/kg and even greater than 0.175 mg/kg were associated with mild and severe effects respectively. Actual dosage received by children may have been considerably lower than estimated since incomplete injection in many cases was suspected. Regardless, adverse events reported were generally mild and self-limited. Few children required hospitalization. Adverse reactions reported were dilated pupils (43%), tachycardia (39%), dry membranes (35%), flushed skin (20%), temperature 37.8° C or 100° F (4%), and neurologic abnormalities (5%). There was also local pain and swelling. In patients with electrocardiograms, 22 of 91 (24%) children had severe tachycardia of 160-190 bpm. Neurologic abnormalities consisted of irritability, agitation, confusion, lethargy, and ataxia. Atropine 2mg is only approved for pediatric patients weighing more than 41kg at the recommended dosing.

7 DRUG INTERACTIONS

7.1 Pralidoxime

When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone because pralidoxime may potentiate the effect of atropine. Excitement and manic behavior immediately following recovery of consciousness have been reported in several cases. However, similar behavior has occurred in cases of organophosphate poisoning that were not treated with pralidoxime.

7.2 Barbiturates

Barbiturates are potentiated by the anticholinesterases; therefore, barbiturates should be used cautiously in the treatment of convulsions resulting from exposure to Atropine.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Atropine readily crosses the placental barrier and enters fetal circulation. There are no adequate data on the developmental risk associated with the use of atropine in pregnant women. Adequate animal reproduction studies have not been conducted with atropine.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

8.2 Lactation

Risk Summary

Atropine has been reported to be excreted in human milk. There are no data on the effects of atropine on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Atropine and any potential adverse effects on the breastfed infant from Atropine or from the underlying maternal condition.

8.4 Pediatric Use

Safety and effectiveness of the 2 mg Atropine autoinjector in pediatric patients weighing less than or equal to 41 kg (90 pounds) have not been established.

Safety and effectiveness of atropine in patients weighing more than 41 kg (90 pounds) are supported by published literature. Adverse reactions seen in pediatric patients are similar to those that occur in adult patients. However, central nervous system effects are often seen earlier, and pediatric patients may be more susceptible to the pharmacologic effects of atropine [*see Adverse Reactions (6)*].

Although the 2 mg Atropine autoinjector is not approved for pediatric patients less than 41 kg, overheating (atropine fever) caused by suppression of sweat gland activity may be more pronounced in infants and small children. Extreme hyperthermia in a newborn has been reported with as little as 0.065 mg orally.

8.5 Geriatric Use

Geriatric patients may be more susceptible to the pharmacologic effects of atropine [*see Adverse Reactions (6)*].

10 OVERDOSAGE

10.1 Symptoms

Manifestations of atropine overdose are dose-related and include flushing, dry skin and mucous membranes, tachycardia, widely dilated pupils that are poorly responsive to light, blurred vision, and fever (which can sometimes be dangerously elevated). Locomotor difficulties, disorientation, hallucinations, delirium, confusion, agitation, coma, and central depression can occur and may last 48 hours or longer. In instances of severe atropine intoxication, respiratory depression, coma, circulatory collapse, and death may occur.

10.2 Treatment

Supportive treatment should be administered as indicated. If respiration is depressed, artificial respiration with oxygen is necessary. Ice bags, alcohol sponges, or a hypothermia blanket may be required to reduce fever, especially in pediatric patients. Catheterization may be necessary if urinary retention occurs. Since atropine elimination takes place through the kidney, urinary output must be maintained and increased if possible; however, dialysis has not been shown to be helpful in overdose situations. Intravenous fluids may be indicated. Because of atropine-induced photophobia, the room should be darkened.

A benzodiazepine may be needed to control marked excitement and convulsions. However, large doses for sedation should be avoided because the central nervous system depressant effect may coincide with the depressant effect occurring late in severe atropine poisoning. Barbiturates are potentiated by the anticholinesterases; therefore, barbiturates should be used cautiously in the treatment of convulsions. Central nervous system stimulants are not recommended.


11 DESCRIPTION

The Atropine prefilled autoinjector is a single dose, self-contained unit designed for self or caregiver administration.

Each 2 mg Atropine autoinjector delivers 1.67 mg atropine (equivalent to 2 mg atropine sulfate) in 0.7 mL of sterile pyrogen-free solution for intramuscular injection. Each 2 mg autoinjector also contains the following inactive ingredients: 3.27 mg citric acid monohydrate (buffer), 12.47 mg glycerin, 2.8 mg phenol, and 3.05 mg sodium citrate dihydrate (buffer). The pH range is 4.1 - 4.5.

Atropine, a cholinergic muscarinic antagonist, occurs as white crystals, usually needle-like, or as a white, crystalline powder. It is highly soluble in water with a molecular weight of 289.38. Atropine, a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and l-hyoscyamine; its activity is due almost entirely to the levo isomer of the drug.

Chemically, atropine is designated as *1αH,5αH*-tropan-3-ol (±)-tropate (ester). Its empirical formula is C₁₇H₂₃NO₃ and its structural formula is:



12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Atropine competitively blocks the effects of acetylcholine, including excess acetylcholine due to organophosphorus poisoning, at muscarinic cholinergic receptors on smooth muscle, cardiac muscle, secretory gland cells, and in peripheral autonomic ganglia and the central nervous system.

12.2 Pharmacodynamics

Atropine reduces secretions in the mouth and respiratory passages, relieves the constriction and spasm of the respiratory passages, and may reduce the paralysis of respiration that results from toxic nerve agents which increase anticholinesterase activity in the central nervous system. Atropine-induced parasympathetic inhibition may be preceded by a transient phase of stimulation, especially on the heart where small doses first slow the rate before characteristic tachycardia develops because of paralysis of vagal control. Although mild vagal excitation occurs, the increased respiratory rate and occasionally increased depth of respiration produced by atropine are more probably the result of bronchiolar dilatation. Accordingly, atropine is an unreliable respiratory stimulant, and large or repeated doses may depress respiration.

Adequate doses of atropine can prevent or abolish various types of reflex vagal cardiac slowing or asystole. The drug also can prevent or abolish bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine may also lessen the degree of partial heart block when vagal activity is an etiologic factor. In some individuals with complete heart block, the idioventricular rate may be accelerated by atropine; in others, the rate is stabilized. In some patients with conduction defects, atropine may cause paradoxical atrioventricular (A-V) block and nodal rhythm.

Systemic doses of atropine slightly raise systolic and lower diastolic pressures and can produce significant postural hypotension. Such doses also slightly increase cardiac output and decrease central venous pressure. Atropine can dilate cutaneous blood vessels, particularly in the “blush” area (atropine flush), and may cause overheating due to suppression of sweat gland activity [see *Warnings and Precautions* (5.2)].

12.3 Pharmacokinetics

Atropine is well absorbed after intramuscular administration. Atropine is distributed throughout the various body tissues and fluids. Much of the drug is metabolized by enzymatic hydrolysis, particularly in the liver; from 13 to 50% is excreted unchanged in the urine. Atropine has been reported to be excreted in human milk [see *Use in Specific Populations* (8.2)]. Atropine readily crosses the placental barrier and enters the fetal circulation.

The approximate C_{max} of atropine following 1.67 mg atropine given intramuscularly to adults by the 2 mg AtroPen[®] delivery system was 9.6 ± 1.5 (mean ± SEM) ng/mL. The mean T_{max} was 3 minutes. The T_{1/2} of intravenous atropine in pediatric subjects over 2 years is 2.5 ± 1.2 (mean ± SD) hours; in adults 16–58 years the T_{1/2} is 3.0 ± 0.9 (mean ± SD) hours; in geriatric patients 65–75 years it is 10.0

± 7.3 (mean ± SD) hours. The protein binding of atropine is 14 to 22% in plasma. There are gender differences in the pharmacokinetics of atropine. The AUC(0-inf) and C_{max} were 15% higher in females than males. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

No adequate studies regarding the carcinogenic potential of atropine have been conducted.

Mutagenesis

Studies to assess the mutagenic potential of atropine have not been conducted.

Impairment of Fertility

In studies in which male rats were orally administered atropine (62.5 to 125 mg/kg) for one week prior to mating and throughout a 5-day mating period with untreated females, a dose-related decrease in fertility was observed. A no-effect dose for male reproductive toxicity was not established. The lowest dose tested was approximately 300 times (on a mg/m² basis) the dose of atropine in a single autoinjector application.

Fertility studies of atropine in females have not been conducted.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

The 2 mg Atropine autoinjector provides atropine base 1.67 mg/0.7 mL (equivalent to atropine sulfate 2 mg/0.7 mL) in a sterile solution for intramuscular injection.

The 2 mg Atropine autoinjector is supplied as 480 self-contained single-dose autoinjectors per box (NDC 71053-592-01).

16.2 Storage and Handling

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Do Not Freeze.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Instructions for Use).

Administration

Ensure that users understand the indications for and use of Atropine, including review of symptoms of poisoning and operation of the Atropine autoinjector [see *Dosage and Administration (2.2)*].

Seek Definitive Medical Care

If feasible and appropriate, advise patients that Atropine is an initial emergency treatment, that they need additional care at a healthcare facility.

Avoid Overheating

If feasible and appropriate, advise the patient to avoid a hot environment and excessive physical activity since atropine can inhibit sweating which can lead to overheating and heat injury.

Manufactured by:
RAFA LABORATORIES, LTD.
JERUSALEM, ISRAEL

ATROPINE INJECTION 2 mg / 0.7 mL (AUTOINJECTOR)

Each autoinjector delivers 1.67 mg Atropine (equivalent to 2 mg Atropine Sulfate),
3.27 mg citric acid monohydrate, 12.47 mg glycerin, 2.8 mg phenol
and 3.05 mg sodium citrate dihydrate

For Intramuscular use only

Rx Only

for use in NERVE AGENT and INSECTICIDE POISONING
NSN 6505-31-017-0350

480 EA

NDC 71053-592-01



Lot No.

Exp. MMMYYYY

See prescribing information

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F)

DO NOT FREEZE.

Manufactured by Rafa Laboratories, Jerusalem, Israel

201002-SA3

(b) (4)

59.5x100 mm**ATROPINE INJECTION 2 mg / 0.7 mL (AUTOINJECTOR)**

Each autoinjector delivers 1.67 mg Atropine (equivalent to 2 mg Atropine Sulfate),
3.27 mg citric acid monohydrate, 12.47 mg glycerin, 2.8 mg phenol
and 3.05 mg sodium citrate dihydrate

For Intramuscular use only

Rx Only

for use in NERVE AGENT and INSECTICIDE POISONING
NSN 6505-31-017-0350

40 EA



Lot No.

Exp. MMMYYYY

See prescribing information

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F)

DO NOT FREEZE.

Manufactured by Rafa Laboratories, Jerusalem, Israel

201002-SA3

(b) (4)



Gurpreet
Gill Sangha

Digitally signed by Gurpreet Gill Sangha

Date: 2/27/2023 11:25:58AM

GUID: 5135f2ad000117842392c50c36c7f28a